Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05518123




Registration number
NCT05518123
Ethics application status
Date submitted
23/08/2022
Date registered
26/08/2022
Date last updated
21/06/2024

Titles & IDs
Public title
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
Scientific title
A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With a History of Inadequate Response to Oral Preventive Medications
Secondary ID [1] 0 0
C4951012
Secondary ID [2] 0 0
BHV3000-407
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Migraine 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rimegepant
Treatment: Drugs - Placebo

Experimental: Rimegepant 75 mg -

Placebo comparator: Placebo -


Treatment: Drugs: Rimegepant
Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase

Treatment: Drugs: Placebo
Matching placebo with every other day dosing during DBT phase
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Compare the efficacy of rimegepant (75 mg) to placebo
Timepoint [1] 0 0
Week 1 to 12 of DBT Phase

Eligibility
Key inclusion criteria
1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
2. Migraine attacks, on average, lasting about 4 - 72 hours, if untreated.
3. 4 to 14 migraine days per month, on average, across the 3 months prior to the Screening Visit (month is defined as 28-days for the purpose of this protocol).
4. Less than15 headache days (migraine or non-migraine) per month in each of the 3-months prior to the Screening Visit and throughout the Screening Phase.
5. Subjects must be able to distinguish migraine attacks from tension/cluster headaches. Prior inadequate response, within 10 years of the Screening Visit, to agents across 2-4 categories of recognized, orally-administered, migraine-preventive medications where at least one example of prior inadequate response is due to lack of efficacy or prior intolerance (not contraindication).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. History of cluster headaches, basilar migraine (migraine with brainstem aura), or hemiplegic migraine.
2. Current medication overuse headaches.
3. 15 or more headache days (migraine or non-migraine) per month in any of the 3-months prior to the Screening Visit or during the 28- day Observation Phase.
4. Inadequate response (due to lack of efficacy, prior intolerance, or contraindication) to agents across > 4 categories of recognized, orally administered, migraine-preventive medications.
5. Active chronic pain syndrome (such as fibromyalgia, chronic pelvic pain, complex regional pain syndrome [CRPS]).
6. Other pain syndromes (including trigeminal neuralgia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, interfere with study assessments of safety or efficacy.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/11/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
11/02/2025
Actual
Sample size
Target
600
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Recruitment hospital [1] 0 0
Genesis Research Services - Broadmeadow
Recruitment hospital [2] 0 0
Genesis Research Services - Newcastle
Recruitment hospital [3] 0 0
USC Clinical Trials Sunshine Coast - Sippy Downs
Recruitment hospital [4] 0 0
PainMedSA & CerCare Pty Ltd - Wayville
Recruitment postcode(s) [1] 0 0
2292 - Broadmeadow
Recruitment postcode(s) [2] 0 0
2292 - Newcastle
Recruitment postcode(s) [3] 0 0
4556 - Sippy Downs
Recruitment postcode(s) [4] 0 0
5034 - Wayville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
Nevada
Country [8] 0 0
United States of America
State/province [8] 0 0
New Mexico
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Austria
State/province [15] 0 0
Tirol
Country [16] 0 0
Austria
State/province [16] 0 0
Klagenfurt am Wörthersee
Country [17] 0 0
Austria
State/province [17] 0 0
Vienna
Country [18] 0 0
Belgium
State/province [18] 0 0
Brussels
Country [19] 0 0
Belgium
State/province [19] 0 0
Antwerpen
Country [20] 0 0
Belgium
State/province [20] 0 0
Brugge
Country [21] 0 0
Belgium
State/province [21] 0 0
Brussel
Country [22] 0 0
Belgium
State/province [22] 0 0
Hasselt
Country [23] 0 0
Belgium
State/province [23] 0 0
Liège
Country [24] 0 0
Belgium
State/province [24] 0 0
Saint Nicolas Province De Liège
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
Canada
State/province [26] 0 0
Quebec
Country [27] 0 0
Denmark
State/province [27] 0 0
Capital Region
Country [28] 0 0
Denmark
State/province [28] 0 0
Region Hovedstaden
Country [29] 0 0
Denmark
State/province [29] 0 0
Copenhagen
Country [30] 0 0
Denmark
State/province [30] 0 0
Viborg
Country [31] 0 0
Finland
State/province [31] 0 0
Uusimaa
Country [32] 0 0
Finland
State/province [32] 0 0
Helsinki
Country [33] 0 0
Finland
State/province [33] 0 0
Tampere
Country [34] 0 0
Finland
State/province [34] 0 0
Turku
Country [35] 0 0
Germany
State/province [35] 0 0
Baden-wuerttemberg
Country [36] 0 0
Germany
State/province [36] 0 0
Hessen
Country [37] 0 0
Germany
State/province [37] 0 0
Mecklenburg-vorpommern
Country [38] 0 0
Germany
State/province [38] 0 0
Niedersachsen
Country [39] 0 0
Germany
State/province [39] 0 0
Sachsen
Country [40] 0 0
Germany
State/province [40] 0 0
Bad Homburg Hessen
Country [41] 0 0
Germany
State/province [41] 0 0
Berlin
Country [42] 0 0
Germany
State/province [42] 0 0
Böhlen Sachsen
Country [43] 0 0
Germany
State/province [43] 0 0
Frankfurt
Country [44] 0 0
Germany
State/province [44] 0 0
Greifswald
Country [45] 0 0
Germany
State/province [45] 0 0
Ulm Baden-Wuerttemberg
Country [46] 0 0
Germany
State/province [46] 0 0
Westerstede
Country [47] 0 0
Germany
State/province [47] 0 0
Wiesbaden Hessen
Country [48] 0 0
Italy
State/province [48] 0 0
MI
Country [49] 0 0
Italy
State/province [49] 0 0
Modena
Country [50] 0 0
Italy
State/province [50] 0 0
Naples
Country [51] 0 0
Italy
State/province [51] 0 0
Pavia
Country [52] 0 0
Italy
State/province [52] 0 0
RM
Country [53] 0 0
Italy
State/province [53] 0 0
Rome/lazio
Country [54] 0 0
Italy
State/province [54] 0 0
Florence
Country [55] 0 0
Italy
State/province [55] 0 0
Milan
Country [56] 0 0
Italy
State/province [56] 0 0
Rome
Country [57] 0 0
Mexico
State/province [57] 0 0
Ciudad DE Mexico
Country [58] 0 0
Mexico
State/province [58] 0 0
Estado DE Mexico
Country [59] 0 0
Mexico
State/province [59] 0 0
Yucatan
Country [60] 0 0
Mexico
State/province [60] 0 0
Aguascalientes
Country [61] 0 0
Mexico
State/province [61] 0 0
Mexico City
Country [62] 0 0
Poland
State/province [62] 0 0
Kujawsko-pomorskie
Country [63] 0 0
Poland
State/province [63] 0 0
Lubuskie
Country [64] 0 0
Poland
State/province [64] 0 0
Malopolska
Country [65] 0 0
Poland
State/province [65] 0 0
Mazowieckie
Country [66] 0 0
Poland
State/province [66] 0 0
Katowice
Country [67] 0 0
Poland
State/province [67] 0 0
Kraków
Country [68] 0 0
Poland
State/province [68] 0 0
Szczecin
Country [69] 0 0
Poland
State/province [69] 0 0
Warszawa
Country [70] 0 0
Poland
State/province [70] 0 0
Wroclaw
Country [71] 0 0
Poland
State/province [71] 0 0
Lódzkie
Country [72] 0 0
Spain
State/province [72] 0 0
Alicante
Country [73] 0 0
Spain
State/province [73] 0 0
Madrid, Comunidad DE
Country [74] 0 0
Spain
State/province [74] 0 0
València
Country [75] 0 0
Spain
State/province [75] 0 0
Barcelona
Country [76] 0 0
Spain
State/province [76] 0 0
Madrid
Country [77] 0 0
Spain
State/province [77] 0 0
Santander
Country [78] 0 0
Spain
State/province [78] 0 0
Sevilla
Country [79] 0 0
Spain
State/province [79] 0 0
Valencia
Country [80] 0 0
Spain
State/province [80] 0 0
Valladolid
Country [81] 0 0
Sweden
State/province [81] 0 0
Stockholms LÄN [se-01]
Country [82] 0 0
Sweden
State/province [82] 0 0
Uppsala LÄN [se-03]
Country [83] 0 0
Sweden
State/province [83] 0 0
Goteborg
Country [84] 0 0
Sweden
State/province [84] 0 0
Gothenburg
Country [85] 0 0
Sweden
State/province [85] 0 0
Lund
Country [86] 0 0
Sweden
State/province [86] 0 0
Stockholm
Country [87] 0 0
Sweden
State/province [87] 0 0
Uppsala
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Birmingham
Country [89] 0 0
United Kingdom
State/province [89] 0 0
EAST Riding
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Norfolk
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Northamptonshire
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Other
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Oxfordshire
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Bristol
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Hull
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Liverpool
Country [97] 0 0
United Kingdom
State/province [97] 0 0
London
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Sunderland, Tyne & Wear
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Swinton, Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
Trial website
https://clinicaltrials.gov/study/NCT05518123
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Pfizer Pfizer CT.gov Call Center
Address 0 0
Country 0 0
Phone 0 0
1-800-718-1021
Fax 0 0
Email 0 0
ClinicalTrials.gov_Inquiries@pfizer.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05518123